Takeda withdraws dengue vaccine applications in US and Singapore

Takeda Healthcare Philippines announced on Thursday that it voluntarily withdrew its dengue vaccine applications in the US and Singapore due to requested data collection issues.

The company, which manufactures Qdenga (TAK-003), is still awaiting approval from the Philippine Food and Drug Administration (FDA) for CPR.

Health Secretary Teodoro Herbosa stated that Takeda must submit a risk management plan and explain its withdrawal in other countries before the FDA can issue the CPR.

The Department of Health reported 123,191 dengue cases nationwide from January to June this year, with an increase among children aged 5 to 9 years old.

Once approved, Qdenga will be administered through clinics rather than mass immunization programs to determine individuals' serologic status before vaccination.